A pharmacokinetic study on red ginseng with furosemide in equine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwak, Young Beom | - |
dc.contributor.author | Lee, Eunkyu | - |
dc.contributor.author | Choi, Hyunjoo | - |
dc.contributor.author | Park, Taemook | - |
dc.contributor.author | Kim, Ahram | - |
dc.contributor.author | Kim, Jungon | - |
dc.contributor.author | Yoon, Jungho | - |
dc.contributor.author | Yoo, Hye Hyun | - |
dc.date.accessioned | 2024-01-20T09:03:21Z | - |
dc.date.available | 2024-01-20T09:03:21Z | - |
dc.date.issued | 2023-11 | - |
dc.identifier.issn | 2297-1769 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/117856 | - |
dc.description.abstract | Red ginseng (RG) is a popular ingredient in traditional Korean medicine that has various health benefits. It is commonly taken orally as a dietary supplement; however, its potential interactions with concomitantly administered drugs are unclear. In this study, we examined the pharmacokinetic interaction between furosemide and RG in equine plasma. Liquid chromatography with tandem mass spectrometry analysis was performed to evaluate ginsenosides in the plasma of horses after feeding them RG and furosemide and validate the results. A single bolus of furosemide (0.5 mg/kg) was administered intravenously to female horses that had consumed RG (600 mg/kg/day) every morning for 3 weeks (experimental group), and blood samples were collected from 0 to 24 h, analyzed, and compared with those from female horses that did not consume RG (control group). Four (20s)-protopanaxadiol ginsenosides (Rb1, Rb2, Rc, and Rd) were detected in the plasma. Rb1 and Rc individually showed a high concentration distribution in the plasma. The C-max, AUC(0-t), and AUC(0-infinity) of furosemide was significantly increased in the experimental group (p < 0.05), while the CL, V-z, and V-ss was decreased (p < 0.05, p < 0.01). These changes indicate the potential for pharmacokinetic interactions between furosemide and RG. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Frontiers Media S.A. | - |
dc.title | A pharmacokinetic study on red ginseng with furosemide in equine | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3389/fvets.2023.1319998 | - |
dc.identifier.scopusid | 2-s2.0-85178924755 | - |
dc.identifier.wosid | 001117646400001 | - |
dc.identifier.bibliographicCitation | Frontiers in Veterinary Science, v.10, pp 1 - 7 | - |
dc.citation.title | Frontiers in Veterinary Science | - |
dc.citation.volume | 10 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 7 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Veterinary Sciences | - |
dc.relation.journalWebOfScienceCategory | Veterinary Sciences | - |
dc.subject.keywordPlus | PANAX-GINSENG | - |
dc.subject.keywordPlus | DRUG-INTERACTIONS | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | GINSENOSIDES | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | VIVO | - |
dc.subject.keywordAuthor | red ginseng | - |
dc.subject.keywordAuthor | furosemide | - |
dc.subject.keywordAuthor | herb-drug interaction | - |
dc.subject.keywordAuthor | equine | - |
dc.subject.keywordAuthor | pharmacokinetics | - |
dc.identifier.url | https://www.frontiersin.org/articles/10.3389/fvets.2023.1319998/full | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.